The new and old Europe: East-west split in pharmaceutical spending

Frontiers in Pharmacology

Volumn 7, Issue FEB, 2016, Pages

  Jakovljevic, Mihajlo ^a   Lazarevic, Marija ^a   Milovanovic, Olivera ^a   Kanjevac, Tatjana ^b  

^a University of Kragujevac Medical Faculty   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Centrally planned economy; Eastern Europe; Expenditure; Free market economy; Pharmaceuticals; Spending; Transition; Western Europe

Indexed keywords

EASTERN EUROPE; EUROPE; FUNDING; MARKET; PRESCRIPTION; WESTERN EUROPEAN;

EID: 84961989651     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00018     Document Type: Article

References (48)

1. Ackroyd, R., Mouiel, J., Chevallier, J. M., and Daoud, F. (2006). Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes. Surg. 16, 1488-1503. doi: 10.1381/096089206778870067
2. Berend, I. T. (2006). An Economic History of Twentieth-Century Europe: Economic Regimes from Laissez-Faire to Globalization. Cambridge: Cambridge University Press. doi: 10.1017/cbo9780511800627
3. Carone, G., Schwierz, C., and Xavier, A. (2012). Cost-Containment Policies in Public Pharmaceutical Spending in the EU. European Economy. Available online at: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf. (accessed October 15, 2015).
4. Dagovic, A., Zugic, A., and Jakovljevic, M. (2015). Macroeconomic policy impact on oncology-related public expenditure in an emerging european market-signs of early recovery. Serb. J. Exp. Clin. Res. 16, 43-50. doi: 10.1515/sjecr-2015-0007
5. Deacon, B. (2000). Eastern European welfare states: the impact of the politics of globalization. J. Eur. Soc. Policy 10, 146-161. doi: 10.1177/095892870001000203
6. Ensor, T. (2004). Informal payments for health care in transition economies. Soc. Sci. Med. 58, 237-246. doi: 10.1016/S0277-9536(03)00007-8
7. Ess, S. M., Schneeweiss, S., and Szucs, T. D. (2003). European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21, 89-103. doi: 10.2165/00019053-200321020-00002
8. Getzen, T. E. (1990). Macro forecasting of national health expenditures. Adv. Health Econ. Health Serv. Res. 11, 27-48.
9. Gotseva, A. (2015). Reducing Public Spending at Private Expense? Out-of-Pocket Pharmaceutical Expenditure in Bulgaria after the 1998 Healthcare Reform. Doctoral dissertation, Central European University. Available online at: http://www.etd.ceu.hu/2015/gotseva_adelina.pdf. (accessed October 15, 2015).
10. Healy, J., and McKee, M. (2002). Implementing hospital reform in central and eastern Europe. Health Policy 61, 1-19. doi: 10.1016/S0168-8510(01)00213-5
11. Higgins, M. J., and Graham, S. J. (2009). Intellectual property. Balancing innovation and access: patent challenges tip the scales. Science 326, 370-371. doi: 10.1126/science.1176116
12. Iskrov, G., Miteva-Katrandzhieva, T., and Stefanov, R. (2012). Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy 108, 10-18. doi: 10.1016/j.healthpol.2012.08.013
13. Iskrov, G., and Stefanov, R. (2015). Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in bulgaria. Front. Public Health 3:64. doi: 10.3389/fpubh.2015.00064
14. Jakovljevic, M., Jovanovic, M., Lazic, Z., Jakovljevic, V., Djukic, A., and Velickovic, R. (2011). Current efforts and proposals to reduce healthcare costs in Serbia. Serb. J. Exp. Clin. Res. 12, 161-163. doi: 10.5937/sjecr1104161J
15. Jakovljevic, M., and Laaser, U. (2015). Population aging from 1950 to 2010 in seventeen transitional countries in the wider region of South Eastern Europe. Serb. J. Exp. Clin. Res. doi: 10.4119/UNIBI/SEEJPH-2015-49. [Epub ahead of print].
16. Jakovljevic, M., Rankovic, A., Rancic, N., Jovanovic, M., Ivanovic, M., Gajovic, O., et al. (2013). Radiology services costs and utilization patterns estimates in Southeastern Europe-A retrospective analysis from Serbia. Value Health Regional Issues 2, 218-225. doi: 10.1016/j.vhri.2013.07.002
17. Jakovljevic, M. D., Vukovic, M., and Fontanesi, J. (2015c). Life expectancy and health expenditure evolution in eastern Europe-DiD and DEA analysis. Exp. Rev. Pharmacoecon. Outcomes Res. doi: 10.1586/14737167.2016.1125293. [Epub ahead of print].
18. Jakovljevic, M., Yamada, T., Chen, C. C., Stevanovic, D., Jovanovic, M., Djuricic-Nikic, K., et al. (2015a). Cost-effectiveness of depressive episode pharmacological treatment. Hosp. Pharmacol. 2, 235-245.
19. Jakovljevic, M., Zugic, A., Rankovic, A., and Dagovic, A. (2014a). Radiation therapy remains the key cost driver of oncology inpatient treatment. J. Med. Econ. 18, 29-36. doi: 10.3111/13696998.2014.971162
20. Jakovljevic, M. B. (2013). Resource allocation strategies in Southeastern European health policy. Eur. J. Health Econ. 14, 153-159. doi: 10.1007/s10198-012-0439-y
21. Jakovljevic, M. B. (2014a). Health expenditure dynamics in Serbia 1995-2012. Hosp. Pharmacol. 1, 180-183.
22. Jakovljevic, M. B. (2014b). Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia Health Econ. Ther. Pathways 15, 27-32. doi: 10.7175/fe.v15i1.909
23. Jakovljevic, M. B., and Milovanovic, O. (2015). Growing burden of non-communicable diseases in the emerging health markets: the case of BRICS. Front. Public Health 3:65. doi: 10.3389/fpubh.2015.00065
24. Jakovljevic, M. B., Djordjevic, N., Jurisevic, M., and Jankovic, S. (2015d). Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev. Pharmacoecon. Outcomes Res. 15, 521-530. doi: 10.1586/14737167.2015.1003044
25. Jakovljevic, M. B., Jovanovic, M., and Lesch, M. O. (2015b). Accessibility and affordability of alcohol dependency medical care in Serbia. Front. Psychiatry 5:192. doi: 10.3389/fpsyt.2014.00192
26. Jakovljevic, M. B., Nakazono, S., and Oqura, S. (2014b). Contemporary generic market in Japan-key conditions to successful evolution. Expert Rev. Pharmacoecon. Outcomes Res. 14, 181-194. doi: 10.1586/14737167.2014.881254
27. Jakovljevic, M. M. (2016). Comparison of historical medical spending patterns among the BRICS and G7. J. Med. Econ. 19, 70-76. doi: 10.3111/13696998.2015.1093493
28. Kornai, J., and Eggleston, K. (2001). Welfare, Choice and Solidarity in Transition: Reforming the Health Sector in Eastern Europe. New York, NY: Cambridge University Press. doi: 10.1017/CBO9780511492464
29. Krajewski-Siuda, K., and Romaniuk, P. (2006). Privatisation of hospitals in Poland-barriers and opportunities. Cent. Eur. J. Public Health 14, 25-29.
30. Mackenbach, J. P. (2006). Health Inequalities: Europe in Profile. Produced by COI for the Department of Health. Available online at: http://www.who.int/social_determinants/resources/european_inequalities.pdf. (accessed October 15, 2015).
31. Mossialos, E., Mrazek, M., and Walley, T. (2004). Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity And Quality: Striving for Efficiency, Equity and Quality. Berkshire: McGraw-Hill Education.
32. Mossialos, E., and Oliver, A. (2005). An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int. J. Health Plann. Manage. 20, 291-306. doi: 10.1002/hpm.816
33. Mrazek, M., de Jonchere, K., Petrova, G., and Mossialos, E. (2004). The Pharmaceutical Sector and Regulation in the Countries of Central and Eastern Europe. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Copenhagen: European observatory on health systems and policies, 323-333. Available online at: http://www.euro.who.int/__data/assets/pdf_file/0008/98432/E83015.pdf. (accessed October 15, 2015).
34. Nuijten, M. J. C., Berto, P., Berdeaux, G., Hutton, J., Fricke, F. U., and Villar, F. A. (2001). Trends in decision-making process for pharmaceuticals in Western European countries. Eur. J. Health Econ 2, 162-169. doi: 10.1007/s10198-001-0079-0
35. OECD Pharmaceutical Spending (2013). Availbele online at: https://data.oecd.org/healthres/pharmaceutical-spending.htm. (accessed October 15, 2015).
36. Ogura, S., and Jakovljevic, M. (2014). Health financing constrained by population aging-an opportunity to learn from Japanese experience. Serb. J. Exp. Clin. Res. 15, 175-181. doi: 10.2478/sjecr-2014-0022
37. Petrusic, T., and Jakovljevic, M. (2015). Budget impact of publicly reimbursed prescription medicines in the republic of Srpska. Front. Public Health 3:213. doi: 10.3389/fpubh.2015.00213
38. Putrik, P., Ramiro, S., Kvien, K. T., Sokka, T., Pavlova, M., Uhlig, T., et al. (2014). Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198-206. doi: 10.1136/annrheumdis-2012-202603
39. Rankovic, A., Rancic, N., Jovanovic, M., Ivanovic, M., Gajovic, O., Lazic, Z., et al. (2013). Impact of imaging diagnostics on the budget-are we spending too much? Vojnosanitetski Pregl. 70, 709-711.
40. Rémuzat, C., Urbinati, D., Mzoughi, O., Hammi, E. E., Belgaied, W., and Toumi, M. (2015). Overview of external reference pricing systems in Europe. J. Market Access Health Policy 3, 27675. doi: 10.3402/jmahp.v3.27675
41. Rhodes, T., Ball, A., Stimson, V. G., Kobyshcha, Y., Fitch, C., Pokrovsky, V., et al. (1999). HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction 94, 1323-1336. doi: 10.1046/j.1360-0443.1999.94913235.x
42. Robinson, A. (1994). Rationale for cost-effective laboratory medicine. Clin. Microbiol. Rev. 7, 185-199.
43. Semashko, N. A. (1934). Health Protection in the USSR, 1st Edn. London: Victor Gollancz.
44. Simoens, S., and De Coster, S. (2006). Sustaining generic medicines markets in Europe. J. Generic Med. 3, 257-268. doi: 10.1057/palgrave.jgm.4940128
45. Tambor, M., Pavlova, M., Golinowska, S., and Groot, W. (2015). Can european countries improve sustainability of health care financing through patient cost-sharing? Front. Public Health 3:196. doi: 10.3389/fpubh.2015.00196
46. The World Bank. Country Lending Groups (2015). Available online at: http://data.worldbank.org/about/country-and-lending-groups#Upper_middle_income. (accessed October 15, 15).
47. Torosyan, A., Romaniuk, P., and Krajewski-Siuda, K. (2008). The Armenian healthcare system: recent changes and challenges. J. Public Health 16, 183-190. doi: 10.1007/s10389-007-0160-y
48. World Health Organization, European Health for All database (HFA-DB). (2015). Available online at: http://www.euro.who.int/en/data-and-evidence/databases/european-health-for-all-database-hfa-db. (accessed October 15, 15).